Zacks Investment Research upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a research report sent to investors on Wednesday, January 3rd. The firm currently has $23.00 price objective on the medical equipment provider’s stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
Several other analysts have also issued reports on the company. BidaskClub upgraded Lantheus from a hold rating to a buy rating in a research note on Wednesday, December 27th. ValuEngine lowered Lantheus from a buy rating to a hold rating in a research note on Friday, December 1st. Jefferies Group upped their target price on Lantheus from $22.00 to $27.00 and gave the company a buy rating in a research report on Friday, November 3rd. Credit Suisse Group upped their target price on Lantheus from $19.00 to $23.00 and gave the company a neutral rating in a research report on Friday, November 3rd. Finally, Wells Fargo & Co raised Lantheus from a market perform rating to an outperform rating in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $24.50.
Lantheus (NASDAQ:LNTH) traded up $0.10 on Wednesday, reaching $23.65. The company had a trading volume of 396,900 shares, compared to its average volume of 324,025. Lantheus has a fifty-two week low of $7.95 and a fifty-two week high of $24.10. The company has a market capitalization of $883.27 and a price-to-earnings ratio of 29.56. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.
Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business had revenue of $79.94 million for the quarter, compared to analyst estimates of $77.18 million. During the same quarter in the prior year, the company posted $0.15 earnings per share. Lantheus’s revenue was up 9.4% on a year-over-year basis. equities research analysts anticipate that Lantheus will post 1.05 earnings per share for the current year.
In related news, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Michael P. Duffy sold 11,917 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total value of $257,764.71. Following the sale, the insider now directly owns 152,301 shares in the company, valued at approximately $3,294,270.63. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Thrivent Financial For Lutherans acquired a new stake in Lantheus during the second quarter worth approximately $321,000. Royce & Associates LP acquired a new stake in shares of Lantheus in the 2nd quarter valued at $4,896,000. QS Investors LLC acquired a new stake in shares of Lantheus in the 2nd quarter valued at $2,256,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Lantheus in the 2nd quarter valued at $770,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Lantheus in the 2nd quarter valued at $835,000. 91.91% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Lantheus (LNTH) Rating Increased to Buy at Zacks Investment Research” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2018/01/12/lantheus-lnth-upgraded-by-zacks-investment-research-to-buy.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.